Simultaneous PTHrp- and calcitriol-mediated hypercalcemia associated with probable spontaneous transformation of lung adenocarcinoma to squamous cell carcinoma: A case report

被引:0
作者
Yu, Run [1 ]
机构
[1] UCLA, David Geffen Sch Med, Div Endocrinol, 200 Med Plaza Dr,Suite 530, Los Angeles, CA 90095 USA
来源
CURRENT PROBLEMS IN CANCER: CASE REPORTS | 2024年 / 14卷
关键词
Lung adenocarcinoma; Lung squamous cell carcinoma; Hypercalcemia; Parathyroid hormone-related protein; Calcitriol; CANCER;
D O I
10.1016/j.cpccr.2024.100289
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hypercalcemia is a common paraneoplastic syndrome. Malignancies cause hypercalcemia by various mechanisms. Usually a single mechanism underlies paraneoplastic hypercalcemia. Two simultaneous mechanisms associated with one malignancy, however, are occasionally encountered. Here a rare case is reported to describe simultaneous PTHrp- and calcitriol-mediated hypercalcemia associated with probable spontaneous transformation of lung adenocarcinoma to squamous cell carcinoma. This 81-year-old male with history of resected lung adenocarcinoma developed hypercalcemia. The peak albumin-corrected calcium was 13.4 mg/dL (normal 8.6-10.4) with ionized calcium 1.70 mmol/L (normal 1.09-1.29). Laboratory tests showed PTH 7 pg/ml (normal 11-51), PTHrP 43.7 pmol/L (normal <2.3), 25-hydroxyvitamin D 33 ng/ml (normal 20-50), 1,25-dihydroxyvitamin D 71.0 pg/ml (19.9-79.3), TSH 3.1 <mu>IU/mL (normal 0.3-4.7). CT showed new right lower lobe lung masses, paraesophageal and pericaval lymph nodes, and a cranial lesion. Biopsy of a lung mass revealed predominantly squamous cell carcinoma. He was treated with intravenous fluid and zoledronate with normalization of calcium levels. Vitamin D supplement was discontinued. The patient's clinical condition deteriorated before chemotherapy was started. He died shortly after comfort care was initiated. Pursuing multiple causes of paraneoplastic hypercalcemia is worthwhile as the treatment towards each mechanism is different.
引用
收藏
页数:3
相关论文
共 15 条
  • [1] Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase
    Adams, J. S.
    Hewison, M.
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2012, 523 (01) : 95 - 102
  • [2] Hyponatremia and hypercalcemia: a study of a large cohort of patients with lung cancer
    Chan, Vanessa W. Q.
    Henry, Michael T.
    Kennedy, Marcus P.
    [J]. TRANSLATIONAL CANCER RESEARCH, 2020, 9 (01) : 222 - 230
  • [3] FISKEN RA, 1981, LANCET, V1, P202
  • [4] Cancer-Associated Hypercalcemia
    Guise, Theresa A.
    Wysolmerski, John J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (15) : 1443 - 1451
  • [5] Histologic transformation of non-small-cell lung cancer in brain metastases
    Jiang, Meng
    Zhu, Xiaolong
    Han, Xiao
    Jing, Haiyan
    Han, Tao
    Li, Qiang
    Ding, Xiao
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (04) : 375 - 384
  • [6] A surgical case of lung cancer with poor general status associated with parathyroid hormone-related protein
    Kamata, Toshiko
    Koh, Eitetsu
    Masunaga, Atsuko
    Okabayashi, Asako
    Hasegawa, Mizue
    Katsura, Hideki
    Hiroshima, Kenzo
    Sekine, Yasuo
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 (05) : E372 - E377
  • [7] Kroopnick Jeffrey M, 2021, AACE Clin Case Rep, V7, P200, DOI 10.1016/j.aace.2021.01.003
  • [8] Hypercalcemia of Malignancy: An Update on Pathogenesis and Management
    Mirrakhimov, Aibek E.
    [J]. NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES, 2015, 7 (11) : 483 - 493
  • [9] Parathyroid hormone-related protein varies with sex and androgen status in nonsmall cell lung cancer
    Montgrain, Philippe R.
    Quintana, Rick
    Rascon, Yvette
    Burton, Douglas W.
    Deftos, Leonard J.
    Casillas, Andrea
    Hastings, Randolph H.
    [J]. CANCER, 2007, 110 (06) : 1313 - 1320
  • [10] Nemr S, 2017, CASE REP ONCOL MED, V2017, DOI 10.1155/2017/2583217